» Articles » PMID: 39350911

Whitaker Syndrome: A Case Report of Autoimmune Polyendocrine Syndrome Type 1 with Dilated Cardiomyopathy

Overview
Journal Clin Case Rep
Date 2024 Oct 1
PMID 39350911
Authors
Affiliations
Soon will be listed here.
Abstract

Key Clinical Message: This case report highlights dilated cardiomyopathy as a cardiovascular complication in autoimmune polyendocrine syndrome type 1 (APS-1), emphasizing the need for early recognition and a multidisciplinary approach. Comprehensive care and regular follow-up are crucial in managing these atypical presentations to optimize patient outcomes.

Abstract: APS-1, also known as Whitaker syndrome, is characterized by a triad of mucocutaneous candidiasis, adrenal insufficiency, and hypoparathyroidism. This rare autosomal recessive disorder results from mutations in the autoimmune regulator (AIRE) gene. Cardiovascular and pulmonary manifestations in APS-1 are infrequently reported in the literature. We present a case of a 28-year-old male who presented with shortness of breath and pedal edema. Physical examination revealed alopecia, absence of eyebrows, hyperpigmentation on joints, oral candidiasis, and nail dystrophy. Echocardiography demonstrated dilated cardiomyopathy (DCM) and pericardial effusion. Chest x-ray showed left-sided pleural effusion. Laboratory investigations revealed hypocalcemia, hyperphosphatemia, low parathyroid hormone (PTH), low cortisol, and high adrenocorticotropic hormone (ACTH) levels. The combination of chronic mucocutaneous candidiasis (CMC), hypoparathyroidism, and adrenal insufficiency confirmed the diagnosis of APS-1. To the best of our knowledge, this is the first Pakistani and second worldwide reported case of APS-1 presenting with such a combination of manifestations. Early recognition and multidisciplinary management are crucial for improving outcomes in these patients.

References
1.
Wani A, Farooqui K, Bashir M, Mir S, Lone A, Masoodi S . Autoimmune polyglandular syndrome type 1 with reversible dilated cardiomyopathy: complete recovery after correction of hypocalcemia and hypocortisolemia. J Pediatr Endocrinol Metab. 2013; 26(3-4):373-6. DOI: 10.1515/jpem-2012-0201. View

2.
Husebye E, Perheentupa J, Rautemaa R, Kampe O . Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med. 2009; 265(5):514-29. DOI: 10.1111/j.1365-2796.2009.02090.x. View

3.
Bruserud O, Oftedal B, Landegren N, Erichsen M, Bratland E, Lima K . A Longitudinal Follow-up of Autoimmune Polyendocrine Syndrome Type 1. J Clin Endocrinol Metab. 2016; 101(8):2975-83. PMC: 4971337. DOI: 10.1210/jc.2016-1821. View

4.
Husebye E, Anderson M, Kampe O . Autoimmune Polyendocrine Syndromes. N Engl J Med. 2018; 378(12):1132-1141. PMC: 6007870. DOI: 10.1056/NEJMra1713301. View

5.
Perheentupa J . Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab. 2006; 91(8):2843-50. DOI: 10.1210/jc.2005-2611. View